INDUSTRY INSIGHTS

• A Connected Approach To OSD Development

  See how an integrated OSD development strategy can identify risks early, strengthen process understanding and prepare products for scale-up, tech transfer and commercialization.

• Improving Stability Through Science-Led OSD Reformulation

  A marketed multivitamin tablet spanning a 0.03% to 46% w/w range failed early in accelerated stability testing. Mechanism-led reformulation and a switch to direct compression changed the outcome.

• De-Risking Complex Generic OSD Development

  Complex generic tablet development requires early alignment of regulatory strategy, QbD formulation, discriminatory dissolution, and reference-scaled bioequivalence.

• Accelerating Complex Generic Drug Development Through Advanced Deformulation

  With FDA no longer identifying Q1/Q2 differences, applicants bear the diagnostic burden. Reverse engineering now directly affects development speed, cost, and approval.

• Navigating Complex OSD Challenges With Predictive Insights

  Learn how predictive modeling, advanced material characterization, and data-driven process insights support manufacturing readiness and confident launch decisions.

• Accelerating An Innovative High Potency Oncology Therapy To Market

  Assimilate how disciplined containment, proactive risk management, and collaboration accelerate oncology programs under tight timelines while protecting quality, safety, and global launch readiness.

• HPAPIS Production: "Where Micrograms Matters"

  In HPAPI manufacturing, micrograms make a difference. Risk‑based containment, smart facility design, and exposure limits safeguard people, product, and performance.

• Navigating High-Potency OSD Manufacturing

  Learn how containment strategy, process design, and early risk‑based decisions influence operator protection, compliance, and long‑term manufacturing success as potency levels continue to rise.

• High Potency APIs And The Evolving Demands Of Drug Development

  See how higher API activity is changing expectations around containment, scalability, and cross‑functional alignment — and why early decisions now have a greater impact on long‑term success.

• Advancing High Potency Manufacturing

  Advance potent drug manufacturing through tighter containment, thoughtful process engineering, and closed handling that protects workers while improving efficiency and scale.

• Safely Scaling High Potency API Manufacturing

  Scaling HPAPI production demands disciplined containment and exposure control. Integrated operating models help manage risk while enabling compliant, reliable scale‑up.